Trifluridine for treatment of mpox infection in drug combinations in ophthalmic cell models.
drug combination
monkeypox
ophthalmic infection
tecovirimat resistance
trifluridine
Journal
Journal of medical virology
ISSN: 1096-9071
Titre abrégé: J Med Virol
Pays: United States
ID NLM: 7705876
Informations de publication
Date de publication:
Jan 2024
Jan 2024
Historique:
revised:
23
11
2023
received:
31
08
2023
accepted:
15
12
2023
medline:
5
1
2024
pubmed:
5
1
2024
entrez:
5
1
2024
Statut:
ppublish
Résumé
The Mpox virus can cause severe disease in the susceptible population with dermatologic and systemic manifestations. Furthermore, ophthalmic manifestations of mpox infection are well documented. Topical trifluridine (TFT) eye drops have been used for therapy of ophthalmic mpox infection in patients, however, its efficacy against mpox virus infection in this scenario has not been previously shown. In the present study, we have established ophthalmic cell models suitable for the infection with mpox virus. We show, that TFT is effective against a broad range of mpox isolates in conjunctival epithelial cells and keratocytes. Further, TFT remained effective against a tecovirimat-resistant virus strain. In the context of drug combinations, a nearly additive effect was observed for TFT combinations with brincidofovir and tecovirimat in conjunctival epithelial cells, while a slight antagonism was observed for both combinations in keratocytes. Altogether, our findings demonstrate TFT as a promising drug for treatment of ophthalmic mpox infection able to overcome tecovirimat resistance. However, conflicting results regarding the effect of drug combinations with approved compounds warrant close monitoring of such use in patients.
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
e29354Informations de copyright
© 2024 The Authors. Journal of Medical Virology published by Wiley Periodicals LLC.
Références
Mitjà O, Ogoina D, Titanji BK, et al. Monkeypox. Lancet. 2023;401:60-74.
Kaufman AR, Chodosh J, Pineda R. Monkeypox virus and ophthalmology - a primer on the 2022 monkeypox outbreak and monkeypox-related ophthalmic disease. JAMA Ophthalmol. 2023;141:78-83.
Hughes C, McCollum A, Pukuta E, et al. Ocular complications associated with acute monkeypox virus infection DRC. Int J Infect Dis. 2014;21:276-277.
Perzia B, Theotoka D, Li K, et al. Treatment of ocular-involving monkeypox virus with topical trifluridine and oral tecovirimat in the 2022 monkeypox virus outbreak. Am J Ophthalmol Case Rep. 2023;29:101779.
Abdelaal A, Serhan HA, Mahmoud MA, Rodriguez-Morales AJ, Sah R. Ophthalmic manifestations of monkeypox virus. Eye. 2023;37:383-385.
Shyr ZA, Cheng YS, Lo DC, Zheng W. Drug combination therapy for emerging viral diseases. Drug Discov Today. 2021;26:2367-2376.
Boikova D, Marco B, Tamara R. Drug sensitivity of currently circulating Mpox viruses. N Engl J Med. 2023;388:279-281.
Boikova D, Zöller N, Tietgen M, et al. Repurposing of the antibiotic nitroxoline for the treatment of mpox. J Med Virol. 2023;95:e28652.
Chou TC. Theoretical basis, experimental design, and computerized simulation of synergism and antagonism in drug combination studies. Pharmacol Rev. 2006;58:621-681.
Hishiki T, Morita T, Akazawa D, et al. Identification of IMP dehydrogenase as a potential target for anti-Mpox virus agents. Microbiol Spectr. 2023;11(4):e0056623.
Kern ER. In vitro activity of potential anti-poxvirus agents. Antiviral Res. 2003;57(1-2):35-40.
Kataoka Y, Iimori M, Niimi S, et al. Cytotoxicity of trifluridine correlates with the thymidine kinase 1 expression level. Sci Rep. 2019;9:7964.
Lyseng-Williamson KA, Burness CB, Duggan ST. Trifluridine/tipiracil in metastatic colorectal cancer: a guide to its use. Drugs Ther Perspect. 2017;33:110-118.
Alarcón J, Kim M, Terashita D, et al. An Mpox-related death in the United States. N Engl J Med. 2023;388:1246-1247.
Garrigues JM, Hemarajata P, Karan A, et al. Identification of tecovirimat resistance-associated mutations in human monkeypox virus - Los Angeles county. Antimicrob Agents Chemother. 2023;67(7):e0056823.
Quenelle DC, Prichard MN, Keith KA, et al. Synergistic efficacy of the combination of ST-246 with CMX001 against orthopoxviruses. Antimicrob Agents Chemother. 2007;51:4118-4124.
Mitjà O, Alemany A, Marks M, et al. Mpox in people with advanced HIV infection: a global case series. Lancet. 2023;401:939-949.
Mumtaz N, Jimmerson LC, Bushman LR, et al. Cell-line dependent antiviral activity of sofosbuvir against Zika virus. Antiviral Res. 2017;146:161-163.
Jia J, Zhu F, Ma X, Cao ZW, Li YX, Chen YZ. Mechanisms of drug combinations: interaction and network perspectives. Nat Rev Drug Discov. 2009;8:111-128.
Chait R, Craney A, Kishony R. Antibiotic interactions that select against resistance. Nature. 2007;446(7136):668-671.